Camlin Fine Sciences Limited has informed the Exchange about Investor Presentation
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Camlin Fine Sciences shared its Q1FY26 investor presentation detailing weak quarterly performance. Revenue stood at Rs. 4,236 mn, down from Rs. 4,375 mn in Q4FY25 but up from Rs. 3,809 mn in Q1FY25. Adjusted EBITDA fell sharply to Rs. 190 mn (margin 4.5%), compared with Rs. 594 mn (13.6%) in the previous quarter. The company reported a loss of Rs. 42.5 mn from continuing operations versus a profit of Rs. 227 mn in Q4FY25. Management attributed the weakness to sluggish demand in specialty ingredient straights, one-time performance bonuses in the blends business, and tariff uncertainty affecting vanillin. The blends business continued to grow strongly, and CFS Vitafor (acquired June 2024) contributed to regional growth. Net Debt/EBITDA improved to 3.1x in FY25 from 5.8x in FY24.
Sharp sequential decline in margins and a return to losses suggest near-term earnings pressure, which is likely to weigh on the stock. However, improving leverage and continued strength in the high-value blends segment provide some medium-term comfort for shareholders.